Search results

  1. Tests to help assess risk of acute kidney injury for people being considered for critical care admission (ARCHITECT and Alinity i Urine NGAL assays, BioPorto NGAL test and NephroCheck test) (DG39)

    Evidence-based recommendations on tests to help assess risk of acute kidney injury for people being considered for critical care admission. The tests are the

  2. Intravenous fluid therapy in children and young people in hospital (NG29)

    This guideline covers general principles for managing intravenous (IV) fluids for children and young people under 16 years, including assessing fluid and electrolyte status and prescribing IV fluid therapy. It applies to a range of conditions and different settings. It does not include recommendations relating to specific conditions. This guideline represents a major opportunity to improve patient safety for children and young people having IV fluid therapy in hospital.

  3. Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632)

    Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in adults who

  4. Joint replacement (primary): hip, knee and shoulder (NG157)

    This guideline covers care before, during and after a planned knee, hip or shoulder replacement. It includes recommendations to ensure that people are given full information about their options for surgery, including anaesthesia. It offers advice for healthcare professionals on surgical procedures and ensuring safety during operations. It also offers guidance on providing support and rehabilitation before and after surgery.

  5. Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)

    Evidence-based recommendations on larotrectinib (Vitrakvi) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and

  6. Current evidence on the safety of percutaneous mechanical thrombectomy for acute deep vein thrombosis (DVT) of the leg shows there are well-recognised but infrequent complications. For acute iliofemoral DVT the evidence on efficacy is limited in quality and quantity, therefore this procedure should only be used with  special arrangements   for clinical governance, consent, and audit or research.

    Recommendation ID IPG651/1 Question Current evidence on the safety of percutaneous mechanical thrombectomy for acute deep vein thrombosis

  7. COVID-19 rapid guideline: chronic kidney disease (NG176)

    The purpose of this guideline is to maximise the safety of adults with chronic kidney disease during the COVID-19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources.

  8. COVID-19 rapid guideline: interstitial lung disease (NG177)

    The purpose of this guideline is to maximise the safety of adults with interstitial lung disease, including idiopathic pulmonary fibrosis and pulmonary sarcoidosis, during the COVID-19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources.

  9. Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)

    Evidence-based recommendations on lorlatinib (Lorviqua) for previously treated ALK-positive advanced non-small-cell lung cancer in adults

  10. Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (TA629)

    Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for follicular lymphoma that has not responded or has progressed up to 6 months

  11. COVID-19 rapid guideline: acute kidney injury in hospital (NG175)

    The purpose of this guideline is to help healthcare professionals prevent, detect and manage acute kidney injury in adults in hospital with known or suspected COVID-19. This is important to improve outcomes and reduce the need for renal replacement therapy.

  12. COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response (NG169)

    The purpose of this guideline is to maximise the safety of children and adults who have dermatological conditions treated with drugs affecting the immune response during the COVID-19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources.

  13. COVID-19 rapid guideline: delivery of systemic anticancer treatments (NG161)

    The purpose of this guideline is to maximise the safety of patients with cancer and make the best use of NHS resources, while protecting staff from infection. It will also enable services to match the capacity for cancer treatment to patient needs if services become limited because of the COVID-19 pandemic.

  14. COVID-19 rapid guideline: managing suspected or confirmed pneumonia in adults in the community (NG165)

    The purpose of this guideline is to ensure the best treatment for adults with suspected or confirmed pneumonia in the community during the COVID-19 pandemic and best use of NHS resources. We have withdrawn our guideline on diagnosing and managing pneumonia in adults until further notice. For general advice on managing COVID-19 symptoms, see the NICE COVID-19 rapid guideline on managing symptoms (including at the end of life) in the community .

  15. COVID-19 rapid guideline: acute myocardial injury (NG171)

    The purpose of this guideline is to help healthcare professionals who are not cardiology specialists identify and treat acute myocardial injury and its cardiac complications in adults with known or suspected COVID-19 but without known pre-existing cardiovascular disease.

  16. COVID-19 rapid guideline: community-based care of patients with chronic obstructive pulmonary disease (COPD) (NG168)

    The purpose of this guideline is to maximise the safety of patients with chronic obstructive pulmonary disease (COPD) during the COVID-19 pandemic, while protecting staff from infection. It will also enable services to make the best use of NHS resources.

  17. Lenalidomide with rituximab for previously treated follicular lymphoma (TA627)

    Evidence-based recommendations on lenalidomide (Revlimid) with rituximab for previously treated follicular lymphoma (grade 1 to 3A) in adults

  18. COVID-19 rapid guideline: severe asthma (NG166)

    The purpose of this guideline is to maximise the safety of adults and children with severe asthma during the COVID-19 pandemic, while protecting staff from infection. It will also enable services to make the best use of NHS resources.

  19. Heavy menstrual bleeding: assessment and management (NG88)

    This guideline covers assessing and managing heavy menstrual bleeding (menorrhagia). It aims to help healthcare professionals investigate the cause of heavy periods that are affecting a woman’s quality of life and to offer the right treatments, taking into account the woman’s priorities and preferences.

  20. COVID-19 rapid guideline: delivery of radiotherapy (NG162)

    The purpose of this guideline is to maximise the safety of patients who need radiotherapy and make the best use of NHS resources, while protecting staff from infection. It will also enable services to match the capacity for radiotherapy to patient needs if services become limited because of the COVID-19 pandemic.

  21. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (NG158)

    This guideline covers diagnosing and managing venous thromboembolic diseases in adults. It aims to support rapid diagnosis and effective treatment for people who develop deep vein thrombosis (DVT) or pulmonary embolism (PE). It also covers testing for conditions that can make a DVT or PE more likely, such as thrombophilia (a blood clotting disorder) and cancer.

  22. Abdominal aortic aneurysm: diagnosis and management (NG156)

    This guideline covers diagnosing and managing abdominal aortic aneurysms. It aims to improve care by helping people who are at risk to get tested, specifying how often to monitor asymptomatic aneurysms, and identifying when aneurysm repair is needed and which procedure will work best.

  23. The percentage of patients with a new diagnosis of depression or anxiety and a FAST score of ≥3 or AUDIT-C score of ≥5 in the preceding 12 months, who have received brief intervention to help them reduce their alcohol related risk within 3 months of the score being recorded.

    The percentage of patients with a new diagnosis of depression or anxiety and a FAST score of ≥3 or AUDIT-C score of ≥5 in the preceding 12 months, who

  24. The percentage of patients with one or more of the following conditions: CHD, atrial fibrillation, chronic heart failure, stroke or TIA, diabetes or dementia with a FAST score of ≥3 or AUDIT-C score of ≥5 in the preceding 2 years who have received brief intervention to help them reduce their alcohol related risk within 3 months of the score being recorded

    The percentage of patients with one or more of the following conditions: CHD, atrial fibrillation, chronic heart failure, stroke or TIA, diabetes or...

  25. The percentage of patients with schizophrenia, bipolar affective disorder and other psychoses aged 25-84 (excluding those with pre-existing CHD, diabetes, stroke and/or TIA) who have had a CVD risk assessment performed in the preceding 12 months (using an assessment tool agreed with NHS England)

    The percentage of patients with schizophrenia, bipolar affective disorder and other psychoses aged 25-84 (excluding those with pre-existing CHD,...